TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness

TG THERAPEUTICS, INC.

2024-Q2 EPS reported -$0.03 revenue$136,939,000

Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.
Raises FY 2024 BRIUMVI revenue target to ~$290-300M, up from $270-290M.
New $250M term loan repays $107M Hercules debt; $100M share repurchase authorized.
Material weakness in ICFR from 2021 restricted stock grant error; immaterial to financials; 10-K/A to be filed.
Phase 1 subcutaneous ublituximab in RMS initiated; FDA IND clearance for azer-cel in progressive MS.

item 1.01 item 1.02 item 2.2 item 2.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.